Key result
Loss of SMAD3 promotes vascular cell proliferation and hypertrophy in pulmonary arterial hypertension via MRTF disinhibition, which was attenuated by MRTF inhibition in animal models.
Loss of SMAD3 promotes vascular remodeling in PAH via MRTF disinhibition, and MRTF inhibition attenuates PAH in preclinical models.
Answers are grounded in this paper and cite their sources.
MRTF inhibition attenuates PAH remodeling in models; leaves open translation to human therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zabini et al. (2017) studied Pulmonary arterial hypertension. MRTF inhibition (CCG1423) and SMAD3 modulation was evaluated on Vascular cell proliferation, hypertrophy, and lung vascular remodeling. Loss of SMAD3 promotes vascular cell proliferation and hypertrophy in pulmonary arterial hypertension via MRTF disinhibition, which was attenuated by MRTF inhibition in animal models.
Synapse has enriched 10 related papers. Consider them for comparative context: